未知生产厂商
ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.
With Multiple Sclerosis, excessive amounts of VLA-4 are believed to mediate the inappropriate migration of lymphocytes into the central nervous system, contributing to the pathogenesis of the disease. The inhibition of VLA-4 may prevent white blood cells from entering sites of inflammation, thereby halting progression of the disease. The mechanism of action of ATL1102 in blocking VLA-4 isdifferent to other drugs in development that target this same protein,including the monoclonal antibody Tysabri(R).
Investigated for use/treatment in asthma and multiple sclerosis.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
